IOVANCE BIOTHERAPEUTICS, INC. - Common Stock (IOVA)

Historical Holders from Q2 2017 to Q2 2025

Symbol
IOVA on Nasdaq
CUSIP
462260100
Type / Class
Equity / Common Stock
Shares outstanding
334M
All holders as of June 30, 2025
Q2 2025
Total 13F shares, excl. options
220M
Holdings value
$379M
% of all portfolios
0.002%
Grand Portfolio weight change
0%
Number of holders
245
Number of buys
126
Number of sells
-151
Average Value change %
0%
Average buys %
+0%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of IOVANCE BIOTHERAPEUTICS, INC. - Common Stock (IOVA)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VANGUARD GROUP INC 7.5% $44.9M 25.1M The Vanguard Group Jun 30, 2025
BlackRock, Inc. 6.4% $38.1M 21.3M BlackRock, Inc. Jun 30, 2025
PERCEPTIVE ADVISORS LLC 3.8% -50% $42.3M -$30.7M 12.8M -42.1% Perceptive Advisors LLC Mar 31, 2025

Institutional Holders of IOVANCE BIOTHERAPEUTICS, INC. - Common Stock (IOVA)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q2 220M $379M -$104M $1.72 245
2025 Q1 239M $798M -$41.5M $3.33 292
2024 Q4 241M $1.79B +$28.5M $7.40 294
2024 Q3 234M $2.2B +$19.3M $9.39 283
2024 Q2 232M $1.86B +$106M $8.02 290
2024 Q1 216M $3.2B +$221M $14.82 273
2023 Q4 195K $1.6M -$122K $8.36 2
2023 Q3 212M $964M +$6.33M $4.55 219
2023 Q2 203M $1.43B -$6.41M $7.04 211
2023 Q1 205M $1.25B +$199M $6.11 223
2022 Q4 172M $1.1B +$102M $6.39 208
2022 Q3 150M $1.44B -$69.2M $9.58 223
2022 Q2 153M $1.69B +$1.89M $11.04 221
2022 Q1 155M $2.57B +$12.4M $16.65 228
2021 Q4 149M $2.83B -$69M $19.09 231
2021 Q3 158M $3.88B -$128M $24.66 236
2021 Q2 160M $4.15B +$95M $26.02 225
2021 Q1 156M $4.93B +$220M $31.66 237
2020 Q4 148M $6.88B +$444M $46.40 258
2020 Q3 140M $4.61B -$20M $32.92 241
2020 Q2 141M $3.88B +$484M $27.45 249
2020 Q1 121M $3.62B -$46.7M $29.94 204
2019 Q4 121M $3.35B +$5.19M $27.68 191
2019 Q3 123M $2.25B +$1.2M $18.20 164
2019 Q2 122M $2.99B +$222M $24.52 159
2019 Q1 115M $1.1B -$11.2M $9.51 145
2018 Q4 119M $1.05B +$237M $8.85 135
2018 Q3 88.2M $992M +$78.6M $11.25 128
2018 Q2 80.9M $1.04B +$53.1M $12.80 121
2018 Q1 77.7M $1.31B +$340M $16.90 118
2017 Q4 57.6M $461M +$15.9M $8.00 84
2017 Q3 55.3M $428M +$58.6M $7.75 85
2017 Q2 47.6M $349M +$349M $7.35 80